TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04546165

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manipulation plus exercise
Description: HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manipulation plus exercise
Description: HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital inhibition plus exercise
Description: Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital inhibition plus exercise
Description: Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
Study: NCT01628601

Intervention type: DRUG
Intervention: Fixed combination 0.3 mg bimatoprost and 5 mg timolol
Description: Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
Study: NCT00101114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00537407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied as a 100 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg tablets
Study: NCT02049619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharyngeal pack
Description: Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
Study: NCT00038779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Study: NCT03096873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
Study: NCT01656226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eryfotona AK-NMSC® cream
Description: Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen SPF 50+
Description: Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
Study: NCT02411929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unlabeled ertugliflozin for oral use
Description: 15 mg oral (3 x 5 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14^C-labeled ertugliflozin for IV use
Description: 100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14^C-labeled ertugliflozin for oral use
Description: 100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Study: NCT03133923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
Description: ≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
Description: ≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)
Description: Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
Study: NCT03343600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 100 mg/tablet, 2 tablets daily
Study: NCT01349491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
Study: NCT03844581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Description: Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propiverine Hydrochloride
Description: propiverine hydrochloride 20 mg/once per day in the morning
Study: NCT03343600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos 2 tablets daily
Study: NCT02544997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: 12mg P.O. for 2wks q21days
Study: NCT05102968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based rehabilitation supporting with the mobile application
Description: For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised rehabilitation by the therapist
Description: For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
Study: NCT02249533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot Light Concussion App
Description: Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
Study: NCT00540345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
Study: NCT03958708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
Study: NCT00540345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
Study: NCT03123042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel basin dissection
Description: Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
Study: NCT00084149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate, Lamivudine, and Zidovudine
Description: antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate, Lamivudine, and Zidovudine
Description: antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: antiretroviral therapy
Study: NCT03407885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled payments for knee and hip replacement
Description: The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices.
Study: NCT01639755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new texture shaped breast implants
Description: breast implant surgery
Study: NCT04408911

Intervention type: DRUG
Intervention: Midazolam vs. Lormetazepam
Description: In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.

Intervention type: DRUG
Intervention: Midazolam vs. Lormetazepam
Description: In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
Study: NCT00575874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone HCl
Description: 0.5 mg rivoglitazone HCl tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.0 mg rivoglitazone HCl tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.5 mg rivoglitazone HCl tablets once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 30 mg capsules once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching tablets or capsule once daily for 12 weeks
Study: NCT03847909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
Study: NCT00348894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: \[S,S\]-reboxetine

Intervention type: DRUG
Group type: OTHER
Intervention: Any
Description: Any standard of care treatment for DPN
Study: NCT01856621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus and charcoal
Description: 2 inhalations as a single dose
Study: NCT02216630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem Cell (ADSC) Therapy
Description: Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
Study: NCT00540345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
Study: NCT03911895

Intervention type: DEVICE
Intervention: Stent more than 26 mn length
Description: stent length in patients undergoing PCI (Drug Eluting Stent)

Intervention type: DEVICE
Intervention: Stent equal to or less than26 mn length
Description: stent length in patients undergoing PCI (Drug Eluting Stent)
Study: NCT00527943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
Study: NCT03973775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Cream 5%
Description: Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Cream 5%
Description: Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
Study: NCT00188513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conformal intensity modulated radiotherapy (IMRT)
Study: NCT03329495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMA-orientated right hemicoloectomy
Description: Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMV-orientated right hemicoloectomy
Description: Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
Study: NCT01707953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to mimic midodrine
Study: NCT02345967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 100 Sensor
Description: One Model 100 Sensor to be implanted per subject.
Study: NCT02497027

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing report released to physician at 4 weeks post enrollment

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing report released to physician at 12 weeks post enrollment
Study: NCT02250443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338 (Bimagrumab)
Study: NCT03444714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiMO-301
Description: Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks
Study: NCT01893073

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful walking program
Study: NCT01742741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
Study: NCT02373020

Intervention type: OTHER
Intervention: colonoscopic biopsies

Intervention type: OTHER
Intervention: colonoscopic biopsies
Study: NCT01888146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain program
Description: Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
Study: NCT03670303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures
Study: NCT01643993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hCG at the Time of Embryo Transfer
Description: hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
Study: NCT00208962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy and blood stem cell transplantation
Description: A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
Study: NCT00629499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 of IV cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
Study: NCT02260726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study: NCT01393808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 1-month Paricalcitol 2mcg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1-month Placebo Treatment